drugset / Trial / NCT05224960
Human Umbilical Cord-derived Mesenchymal Stem Cells for Decompensated Cirrhosis (MSC-DLC-2)
Phase 2
Recruiting
140 enrolled
Beijing 302 Hospital
Chinese PLA General Hospital · collabHainan General Hospital · collabJin Yin-tan Hospital · collabLanZhou University · collabShanghai Changzheng Hospital · collabThird Affiliated Hospital, Sun Yat-Sen University · collabVcanbio Cell and Gene Engineering Corp., Ltd. · collabXinjiang Kashi Area Number 1 Hospital · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Decompensated cirrhosis has a high overall mortality rate. There is a large unmet need for safe and alternative therapeutic potions. This clinical trial is to inspect the efficiency and safety of mesenchymal stem cells (MSCs) therapy for decompensated cirrhosis.
Timeline
- Start
- 2024-06-27
- Primary completion
- 2025-06-27
- Completion
- 2027-06-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | mesenchymal stem cells | Cell therapy | — | Intravenous |